Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: A single institution experience

Journal of Surgical Oncology

Volumn 89, Issue 4, 2005, Pages 239-243

  Moschovi, Maria ^a   Trimis, Georgios ^a   Stefanaki, Kalliopi ^b   Anastasopoulos, John ^b   Syriopoulou, Vassillki ^a   Koultouki, Eleutheria ^a   Tzortzatou Stathopolou, Fotini ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Cisplatin; Ewing sarcoma family tumors; Intensive preoperative chemotherapy; Prognosis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHILD; CLINICAL ARTICLE; EWING SARCOMA; FEMALE; HUMAN; INFANT; MALE; METASTASIS; NEUROECTODERM TUMOR; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTHESIOLOGY; TISSUE NECROSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; SARCOMA, EWING'S; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 14744304243     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20206     Document Type: Article

References (20)

1. Renshaw AA, Perez-Atayde AR, Fletcher JA, et al.: Cytology of typical and atypical Ewing's sarcoma/PNET. Am J Clin Pathol 1996;106:620-624.
2. Alara E, Gerald WL: Molecular biology of the Ewing's sarcoma/ primitive neuroectodermal tumor family. J Clin Oncol 2000;18: 204-213.
3. West DC: Ewing sarcoma family of tumors. Curr Opin Oncol 2000;12:323-329.
4. Paulussen M, Frohlich B, Jurgens H: Ewing tumour: Incidence, prognosis and treatment options. Paediatr Drugs 2001;3:899-913.
5. Zimmermann T, Blutters-Sawatzki R, Flechsenhar K, et al.: Peripheral primitive neuroectodermal tumor: Challenge for multimodal treatment. World J Surg 2001;25:1367-1372.
6. Rosito P, Mancini AF, Rondelli R, et al.: Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: A preliminary report of 6 years of experience. Cancer 1999;86:421-428.
7. Parham DM, Hijazi Y, Steinberg SM, et al.: Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol 1999;30:911-918.
8. Donati D, Zavatta M, Gozzi E, et al.: Modular prosthetic replacement of the proximal femur after resection of a bone tumour a long-term follow-up. J Bone Joint Surg Br 2001;83: 1156-1160.
9. Nesbit ME, Gehan EA, Burget EO, Jr, et al.: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-1674.
10. Hayes FA, Thompson EI, Meyer WH, et al.: Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 1989;7:208-213.
11. Grier HE, Krailo MD, Tarbell NJ, et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing' sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701.
12. McLean TW, Hertel C, Young ML, et al.: Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: The Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol 1999;21:486-493.
13. Bacci G, Ferrari S, Bertoni F, et al.: Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: Recent experience at the istituto Rizzoli. J Clin Oncol 2000;18:885-892.
14. Rodriguez-Galindo C, Spunt S, Pappo A: Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Med Pediatr Oncol 2003;40:276-287.
15. Ettinger LJ, Gaynon PS, Krailo MD, et al.: A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994;73: 1297-1301.
16. Shankar AG, Ashley S, Craft AW, et al.: Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003;40:141-147.
17. Wunder JS, Paulian G, Huvos AG, et al.: The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998;80:1020-1033.
18. Yaniv I, Cohen IJ, Stein J, et al.: Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse. Pediatr Blood Cancer 2004;42:404-409.
19. Jenkin RD, Al-Fawaz I, Al-Shabanah M, et al.: Localized Ewing sarcoma/PNET of bone: Prognostic factors and international data comparison. Med Pediatr Oncol 2002;39:586-593.
20. Cotterill SJ, Ahrens S, Paulussen M, et al.: Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.